Kiara Knuckey

Ms. Kiara Knuckey

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YSYomani Dilukshi Sarathkumara
Yomani Dilukshi Sarathkumara
KKKiara Knuckey
Kiara Knuckey
VLViviana Lutzky
Viviana Lutzky
PGPenny Groves
Penny Groves
MTMaxine Tan
Maxine Tan
Simon H ApteSimon H Apte
Simon H Apte
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with uncertain etiology. Chronic viral infection, including Epstein–Barr virus (EBV), has been implicated as a potential driver of repetitive epithelial injury and dysregulated repair. We sought to evaluate and define the breadth versus specificity of EBV-directed humoral immunity in IPF. We performed proteome-scale serological profiling using an EBV protein microarray (202 proteins) representing all proteins expressed by the EBV proteome (type I and II) on plasma samples from 32 patients with confirmed IPF (87.5% male; mean age 60.9 years) and 15 healthy disease-free controls (40% male; mean age 57.9 years). Per-sample global EBV IgG means were higher in IPF than controls (Welch p = 0.005), and the difference persisted after sex adjustment (p = 0.012). Although no single antigen met a stringent FDR significance threshold, 10 EBV antigen-specific antibody responses showed nominal elevation in IPF, with 2 remaining nominally significant after sex adjustment and 5 additional antibody responses reaching significance only in linear regression models. Overall, these results support the concept that IPF is associated with a diffuse elevation of EBV-directed humoral responses rather than antigen-specific dominance, consistent with ongoing, low-level viral reactivation. The presence of an EBV-negative subgroup within the IPF cohort underscores etiological heterogeneity within IPF.

24 September 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
KKKiara Knuckey
Kiara Knuckey
STSjane Timmins
Sjane Timmins
APAmy Pham
Amy Pham
MTMaxine Tan
Maxine Tan
PGPenny Groves
Penny Groves
Simon H ApteSimon H Apte
Simon H Apte
Repeated molecular sampling of the distal airways is constrained by the invasive nature of bronchoalveolar lavage (BAL), limiting its use in healthy control populations, longitudinal studies, clinical trials and occupational screening. Particles in exhaled air (PExA) sampling offers a non-invasive approach to distal-airway sampling, although whether it captures the same proteins and relative protein abundance as BAL has not been established. We performed the first proof-of-principle high-dimensional proteomic comparison of matched BAL and PExA samples collected from three individuals with silicosis using the SomaScan 11K platform. Within individuals, PExA and BAL shared a substantial subset of detectable proteins and showed similar cross-protein signal patterns, with Pearson correlation coefficients ranging from 0.48 to 0.71. Analytes recurrently detected across all three PExA samples were strongly enriched among those consistently detected in BAL and included pulmonary surfactant proteins and mediators associated with epithelial injury, alveolar macrophage function, inflammation and fibrosis. The PExA findings also showed substantial overlap with an independent published PExA-only proteomic dataset. These proof-of-principle findings show that non-invasive PExA sampling can capture a biologically meaningful subset of the matched BAL proteome. PExA may therefore offer a practical approach for repeated molecular profiling of the distal airways and warrants further evaluation for respiratory biomarker discovery and disease monitoring.

26 June 2026 in Cells
Verified
Journal Article
Open access
PDF file
VLViviana Lutzky
Viviana Lutzky
SRSubash Kumar Rai
Subash Kumar Rai
MTMaxine Tan
Maxine Tan
PGPenny Groves
Penny Groves
KKKiara Knuckey
Kiara Knuckey
DCDan C Chambers
Dan C Chambers
Telomere length (TL) measurement is increasingly used in the evaluation of pulmonary fibrosis and suspected telomere biology disorders, with flow cytometry–fluorescence in situ hybridisation (Flow-FISH) representing the current clinical reference standard. However, Flow-FISH provides a population-averaged relative TL, has a high analytical variability and is largely restricted to PBMC-based measurements. We evaluated a long-read sequencing–based assay, Telo-Seq, for clinical TL assessment in an Australian cohort. In this observational study, TL was measured by both Flow-FISH and Telo-Seq in PBMC from 156 healthy controls and a small cohort of 24 patients undergoing clinical evaluation for interstitial lung disease, using the same blood processing and assay workflows. In an exploratory subset of samples, TL was also assessed in whole lung lavage fluid and explanted lung tissue. In the assessment of PBMC, Telo-Seq correlated with Flow-FISH (R2 ≈ 0.77) and showed lower inter-assay variability (CV ~1.4% vs. ~4.6%). Classification relative to assay-specific age-adjusted 10th-percentile thresholds was largely concordant between Flow-FISH and Telo-Seq, although discordant cases occurred in both directions near clinically relevant thresholds. Long-read sequencing provides a reproducible approach to TL assessment and supports further evaluation in disease-relevant tissues.